• Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo

  • 2024/12/11
  • 再生時間： 5 分
  • ポッドキャスト

Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Combo

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.
    続きを読む 一部表示

あらすじ・解説

On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.
続きを読む 一部表示

Day 4 Highlights from ASH 2024: Pediatric ALL, Epcoritamab, and a Next-Gen CLL Comboに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。